Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), …
– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes.
BridgeBio wins FDA Approval for cardiomyopathy treatment
Nov 26, 2024 · FDA approval for Attruby (Getty Images) The approval should provide competition for Pfizer, who has a very similar treatment on the market. California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an inherited heart condition.
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Nov 25, 2024 · The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval aims to decrease cardiovascular deaths and related hospitalisations.
FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR ...
Nov 25, 2024 · Acoramidis (Attruby; BridgeBio), a drug that stabilizes transthyretin and has demonstrated benefit on cardiovascular outcomes, has been approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). ... Stay up-to-date with breaking news, conference slides, and topical videos ...
BridgeBio heart disease drug Attruby wins FDA approval - STAT
Nov 23, 2024 · The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and...
FDA Nod for BridgeBio Brings New Competition to Blockbuster …
Nov 25, 2024 · BridgeBio set Attruby’s wholesale price at $18,759.12 for a 28-day supply, which works out to about $244,500 annually. That’s a slight discount to Pfizer’s product, priced at $267,987 annually.
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching
Nov 23, 2024 · BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
Nov 23, 2024 · The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can...
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Nov 23, 2024 · BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of...
FDA Approves New Drug for Life-Threatening Heart Condition
Nov 25, 2024 · BridgeBio, the drug’s maker, will be offering a patient support program called ForgingBridges to U.S. patients prescribed Attruby and their families to help them get the therapy with insurance ...